Results 81 to 90 of about 759,990 (316)

Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications

Therapeutic Advances in Vaccines and Immunotherapy
Due to their high specificity and scalability, Monoclonal IgY antibodies have emerged as a valuable alternative to traditional polyclonal IgY antibodies.
Ashraf A. Tabll, Yasser E. Shahein, Mohamed M. Omran, Nahla A. Hussein, Asmaa El-Shershaby, Ana Petrovic, Marija Glasnovic, Robert Smolic, Martina Smolic   +8 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A-Z

, 2014
The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013.
Tansey, EM
core  

Human Monoclonal Antibodies Humoral Immune Response in Patients with Cancer

The monoclonal antibody technology has had a major impact on the serological and biochemical analysis of human tumor antigens. Monoclonal antibodies have rapidly led to the identification and characterization of a large number of antigenic determinants ...
Houghton, Alan N, Cote, Richard J
core   +1 more source

Multiple Tolerization Reduces Antibody Binding Against Tolerogen Cells: Implications for the Production of Monoclonal Antibodies

, 2018
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)CNPq: 425535/2016-9We report an immunization technique that can update the production of monoclonal antibodies (mAbs): the multiple tolerization subtractive immunization (MTSI).
Andrei Moroz, Julia Paiola da Silva, Da Silva, Julia Paiola [UNESP], Fusco-Almeida, Ana Marisa, Elenice Deffune, Da Silva, Julia Paiola, De Lima Fontes, Marina, Moroz, Andrei [UNESP], De Lima Fontes, Marina [UNESP], Marina de Lima Fontes, Nakamura, Cecília Naomi, Deffune, Elenice [UNESP], Cecília Naomi Nakamura, Deffune, Elenice, Matheus Bertanha, Bertanha, Matheus [UNESP], Ana Marisa Fusco-Almeida, Moroz, Andrei, Fusco-Almeida, Ana Marisa [UNESP], Nakamura, Cecília Naomi [UNESP], De Almeida, Rodrigo [UNESP], Bertanha, Matheus, De Almeida, Rodrigo, Rodrigo de Almeida   +23 more
core   +1 more source

Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules [PDF]

, 2011
For efficient prevention of viral infections and cross protection, simultaneous targeting of multiple viral epitopes is a powerful strategy. Llama heavy chain antibody fragments (VHH) against the trimeric envelope proteins of Respiratory Syncytial Virus (
Schepens, B, Temperton, Nigel J., M. Koenders, C. Theo Verrips, Schillemans, J, Ibanez, Lorena Itatı, J. Melero, de Haard, HJ, Verrips, C. Theo, S. Van Gucht, C.T. Verrips, Michael Saunders, Bert Schepens, Temperton, Nigel J, Ibanez, Lorena, Koenders, M, Melero, Jose A., Schepens Bert, de Haard, Hans J, Vanlandschoot, P, Steven Van Gucht, Gonzalez-Pajuelo Maria, Van Gucht, S, Xavier Saelens, Vanlandschoot Peter, Anna Hultberg, B. Schepens, Gonzalez-Pajuelo, Maria, Schillemans Joris, Koenders, Mireille, Nigel J. Temperton, Saunders Michael, Melero José A., de Haard, Hans J., Schillemans, Joris, Ibañez Lorena Itatí, de Haard Hans J., Temperton Nigel J., Ibañez,, Lorena Itatí, H.J. de Haard, Robin A. Weiss, Hultberg, A, Schepens, Bert, C Theo Verrips, N.J. Temperton, Ibanez, LI, Van Gucht, Steven, Verrips, Theo, Maria Gonzalez-Pajuelo, L.I. Ibanez, Rosseels Valérie, José A Melero, Hans J de Haard, Mireille Koenders, Hultberg Anna, Weiss, RA, Saelens Xavier, Saunders, Michael, R.A. Weiss, Weiss Robin A., Saelens, Xavier, Hans J. de Haard, Lorena Itatí Ibañez, A. Hultberg, Gonzalez-Pajuelo, M, Weiss, Robin A., Saelens, X, Joris Schillemans, Verrips, CT, Peter Vanlandschoot, Van Gucht Steven, M. Saunders, Valérie Rosseels, V. Rosseels, Koenders Mireille, Robin A Weiss, P. Vanlandschoot, Rosseels, V, José A. Melero, Hultberg, Anna, M. Gonzalez-Pajuelo, Rosseels, Valerie, J. Schillemans, Ibañez, Lorena Itatí, Melero, Jose Antonio, Vanlandschoot, Peter, Weiss, Robin A, Saunders, M, Nigel J Temperton, X. Saelens, Melero, José A, Verrips C. Theo, Temperton, NJ, Melero, JA, Verrips, C Theo   +94 more
core   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies

Over the past two years our group has taken two distinct approaches in the study of breast cancer: The first is the definition of the antigenic phenotype of breast cancer using mouse monoclonal antibodies as serological probes.
Old, L. J, Oettgen, H. F, Morrissey, D, Cote, R. J, Thomson, T. M, Houghton, A. N, Cordon-Cardo, C   +6 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Monoclonal antibodies for the identification of New World Leishmania species

Memorias do Instituto Oswaldo Cruz, 1996
Monoclonal antibodies specific for selected species complexes of Leishmania have been employed for the characterization of several representative strains of Leishmania isolated from different hosts and localities in the Americas.
Gabriel Grimaldi Jr, Diane McMahon-Pratt
doaj   +1 more source